NCT07088588View on ClinicalTrials.gov

Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

July 31, 2028

Study Completion Date

October 31, 2028

Conditions
Advanced Solid CancerMetastatic Solid TumorOvarian CancerBreast CancerBRCA MutationHRR Deficiency
Interventions
DRUG

SYN608

Patients will orally receive SYN608

Trial Locations (2)

200032

FuDan University Shanghai Cancer Center, Shanghai

200131

Shanghai GoBroad Cancer Hospital China Pharmaceutical University, Shanghai

All Listed Sponsors
lead

Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd

INDUSTRY